Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2025)
Historic Enterprise Value for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$505.7 million.
- Kymera Therapeutics' Enterprise Value rose 805.28% to -$505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$505.7 million, marking a year-over-year increase of 805.28%. This contributed to the annual value of -$488.7 million for FY2024, which is 3037.31% down from last year.
- According to the latest figures from Q3 2025, Kymera Therapeutics' Enterprise Value is -$505.7 million, which was up 805.28% from -$665.4 million recorded in Q2 2025.
- In the past 5 years, Kymera Therapeutics' Enterprise Value ranged from a high of -$333.5 million in Q1 2021 and a low of -$709.0 million during Q1 2025
- For the 5-year period, Kymera Therapeutics' Enterprise Value averaged around -$464.2 million, with its median value being -$442.4 million (2021).
- As far as peak fluctuations go, Kymera Therapeutics' Enterprise Value plummeted by 48898.0% in 2021, and later soared by 2574.83% in 2023.
- Kymera Therapeutics' Enterprise Value (Quarter) stood at -$442.4 million in 2021, then increased by 7.97% to -$407.2 million in 2022, then rose by 7.93% to -$374.9 million in 2023, then crashed by 30.37% to -$488.7 million in 2024, then dropped by 3.47% to -$505.7 million in 2025.
- Its Enterprise Value stands at -$505.7 million for Q3 2025, versus -$665.4 million for Q2 2025 and -$709.0 million for Q1 2025.